When the expression of IGF1 was reduced, women with PCOS may be more sensitive to the treatment of octreotide.36 IGF1 might be attributed to the increase in serum levels of LH and the consequent hyperandrogenic anovulation in women with PCOS.37, 38 The bioavailability of IGF1 has been reported to play a key role in oocyte maturation in PCOS patients.39 The gene discussed is IGF1; the disease is polycystic ovary syndrome.